Table 15Data for ovarian cancer mortality

StudyaStudy DetailsOR95% CICovariatesRegionStudy QualityMeta-Analysis Codeb
Cohort
Survival After Diagnosis of Ovarian Cancer
Nagle, 2008167Cohort of women with ovarian cancer in three Australian states
Exposed: 310 women
Unexposed: 366 women
0.880.70 to 1.11Stage, age group, histologic grade, residual disease, smokingAustralia/NZFair2
Population-Level Mortality
Hannaford, 201033Royal College General Practitioners Oral Contraceptive Study
Exposed: 28,806 women
Unexposed: 17,306 women
0.530.38 to 0.72Age, parity, smoking and social classUKFair2
Vessey, 2010165Oxford Family Planning Association contraception study
602,700 person-years of observation for unexposed and exposed
0.870.79 to 0.96Age, parity, social class, smoking, BMIUKFair2

CI = confidence interval; NZ = New Zealand; OC = oral contraceptive; OR = odds ratio; UK = United Kingdom

a

Study identifies the primary abstracted article. For details about the relationships between companion studies and articles, refer to Tables C-1 and C-2 in Appendix C.

b

Meta-analysis code: 2 = Excluded from the meta-analysis due to differences in study populations.

Study identifies the primary abstracted article. For details about the relationships between companion studies and articles, refer to Tables C-1 and C-2 in Appendix C.

Meta-analysis code: 2 = Excluded from the meta-analysis due to differences in study populations.

From: 2, Oral Contraceptives and Ovarian Cancer

Cover of Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer
Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer.
Evidence Reports/Technology Assessments, No. 212.
Havrilesky LJ, Gierisch JM, Moorman PG, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.